 Crinetics Pharmaceuticals NASDAQ:CRNX was downgraded by stock analysts at BidaskClub from a hold rating to a sell rating in a report issued on Friday, BidAskClub reports. A number of other equities analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Crinetics Pharmaceuticals from a buy rating to a hold rating ... 